Search results for " rifaximin"

showing 2 items of 2 documents

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin

2009

AIM: To estimate the prevalence of small intestinal bacterial overgrowth (SIBO) in our geographical area (Western Sicily, Italy) by means of an observational study, and to gather information on the use of locally active, non-absorbable antibiotics for treatment of SIBO. METHODS: Our survey included 115 patients fulfilling the Rome II criteria for diagnosis of irritable bowel syndrome (IBS); a total of 97 patients accepted to perform a breath test with lactulose (BTLact), and those who had a positive test, received Rifaximin (Normix®, Alfa Wassermann) 1200 mg/d for 7 d; 3 wk after the end of treatment, the BTLact was repeated. RESULTS: Based on the BTLact results, SIBO was present in about 5…

AdultMalemedicine.medical_specialtyConstipationGastroenterologyRifaximinIrritable Bowel SyndromeLactulosechemistry.chemical_compoundAnti-Infective AgentsGastrointestinal AgentsInternal medicineIntestine SmallSmall intestinal bacterial overgrowthmedicineHumansSicilyIrritable bowel syndromeBreath testSettore MED/12 - GastroenterologiaGastrointestinal agentmedicine.diagnostic_testbusiness.industrydigestive oral and skin physiologyGastroenterologyBacterial InfectionsGeneral Medicinemedicine.diseaseRifamycinsLactuloseRifaximinBrief ArticlesBreath TestschemistryEtiologyFemalemedicine.symptombusinessSIBO rifaximinemedicine.drugWorld Journal of Gastroenterology
researchProduct

Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.

2010

Different symptoms have been attributed to uncomplicated diverticular disease (DD). Poor absorbable antibiotics are largely used for uncomplicated DD, mainly for symptom treatment and prevention of diverticulitis onset. Controlled trials on cyclic administration of rifaximin in DD patients were evaluated. Four controlled, including 1 double-blind and 3 open-label, randomized studies were available. Following a long-term cyclic therapy, a significant difference emerged in the global symptoms score (range: 0-18) between rifaximin plus fibers (from 6-6.5 to 1-2) and fibers alone (from 6.7 to 2-3.8), although the actual clinically relevance of such a very small difference remains to be ascertai…

Dietary FiberSettore MED/12 - GastroenterologiaEvidence-Based MedicinePatient SelectionRifamycinsDrug Administration ScheduleRifaximinAnti-Bacterial AgentsDiverticulumSettore MED/18 - Chirurgia GeneraleTreatment Outcomediverticular disease; diverticulitis; haemorrhage; rifaximin; symptoms; therapyHumansDiverticular diseasetherapysymptoms rifaximin diverticulitisDiverticulitis
researchProduct